Generics

Filter

Current filters:

None

Popular Filters

226 to 250 of 1237 results

A tendering system would threaten sustainability of Italian Pharma, argue trade groups

21-11-2013

After extensive assurances from the Italian government that stability would return to the Italian pharmaceutical…

EuropeFinancialGenericsHealthcare

Hikma in $40 million deal to enhance delivery of generic injectables

20-11-2013

USA-based Unilife Corp has signed a long-term commercial supply contract with Jordan-headquartered Hikma…

GenericsHikma PharmaceuticalsLicensingMarkets & MarketingUnilife Corp

DSM and JLL to create pharma services company in $2.6 billion transaction

20-11-2013

USA-based private equity firm JLL Partners and Dutch life and material science group Royal DSM have announced…

DSMGenericsMergers & Acquisitions

Teva updates on Lonquex and Granix launches

Teva updates on Lonquex and Granix launches

18-11-2013

Israel-based Teva Pharmaceutical Industries announced two significant additions to its global oncology…

balugrastimBiosimilarsEuropeGenericsLonquexMarkets & MarketingNorth AmericaOncologyRegulationTeva Pharmaceutical Industries

Mylan launches first generic Focalin XR capsules

Mylan launches first generic Focalin XR capsules

18-11-2013

US generics major Mylan has launched dexmethylphenidate hydrochloride extended-release (ER) capsules,…

Focalin XRGenericsMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartis

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs

18-11-2013

USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

Cadence Pharma leaps on positive patent litigation ruling

17-11-2013

The US District Court for the District of Delaware has ruled in favor of Cadence Pharmaceuticals in the…

Cadence PharmaceuticalsGenericsLegalNeurologicalNorth AmericaOfirmevPatents

Actavis confirms challenge of Lilly’s Axiron patent

Actavis confirms challenge of Lilly’s Axiron patent

14-11-2013

US generics major Actavis confirms that it has filed an Abbreviated New Drug Application with the US…

ActavisAxironEli LillyGenericsLegalMen's HealthNorth AmericaPatentsRegulation

Zimbabwe sees serious drug shortages, as NatPharm fails to meet demand

14-11-2013

A serious shortage of life-saving clinical drugs is having an adverse effect on the health sector in…

FinancialGenericsHealthcareRest of the World

Teva Pharma reaches $718 million tax settlement with Israel State

Teva Pharma reaches $718 million tax settlement with Israel State

12-11-2013

Israel-headquartered global generic drug giant Teva Pharmaceutical Industries has reached an agreement…

FinancialGenericsRest of the WorldTeva Pharmaceutical Industries

FDA takes action to speed safety information updates on generic drugs

FDA takes action to speed safety information updates on generic drugs

11-11-2013

A proposed US Food and Drug Administration rule would speed the dissemination of new safety information…

GenericsMarkets & MarketingNorth AmericaRegulation

Forest Labs settles Bystolic litigation with Actavis

07-11-2013

US drugmaker Forest Laboratories has entered into a settlement agreement with generics drug major Actavis…

ActavisBystolicCardio-vascularForest LaboratoriesGenericsLegalNorth AmericaPatents

Sandoz appeals US court decision on AzaSite patent

Sandoz appeals US court decision on AzaSite patent

06-11-2013

US ophthalmic care specialist InSite Vision says that Sandoz Inc, the US generics unit of Swiss drug…

AzaSiteGenericsInSite VisionLegalNorth AmericaNovartisOphthalmicsPatentsSandoz

Teva results report increase in sales despite flat generic revenues

Teva results report increase in sales despite flat generic revenues

01-11-2013

Still shaken by the sudden resignation of its chief executive this week, Israel-based Teva Pharmaceutical…

FinancialGenericsRest of the WorldTeva Pharmaceutical Industries

India’s Zydus Cadila posts 94% rise in 2nd-qtr net profit

31-10-2013

For the second fiscal quarter ended September 30, 2013, Indian drugmaker Zydus Cadila’s net profit…

FinancialGenericsZydus Cadila

AstraZeneca’s patent protection for Pulmicort Respules upheld by US court

AstraZeneca’s patent protection for Pulmicort Respules upheld by US court

31-10-2013

The US Court of Appeals for the Federal Circuit has reversed and remanded for further proceedings a trial…

AstraZenecaGenericsLegalNorth AmericaPulmicort Respules

Brazilian pharmachemical sector discussed at parliamentary public hearing

31-10-2013

Fiocruz's Production and Innovation in Health vice-president Jorge Bermudez highlighted the importance…

FinancialGenericsProductionSouth America

Teva Pharmaceutical says CEO Jeremy Levin has resigned

Teva Pharmaceutical says CEO Jeremy Levin has resigned

30-10-2013

Israel-based Teva Pharmaceutical Industries, say that, despite its recent denials of a rift with its…

BoardroomGenericsManagementTeva Pharmaceutical Industries

“Generics, Get the Facts Straight” - subject of South Africa workshop

“Generics, Get the Facts Straight” - subject of South Africa workshop

29-10-2013

South Africa’s National Association of Pharmaceutical Manufacturers (NAPM) held a workshop for health…

GenericsPricingRegulationRest of the WorldSouth Africa

Bumper 3rd-qtr for Actavis, with 57% net revenue leap

Bumper 3rd-qtr for Actavis, with 57% net revenue leap

29-10-2013

US generics major Actavis has reported a net revenue increase of 57% to $2.01 billion for the third quarter…

ActavisFinancialGenerics

Japan’s MoF seen as another opponent to premium system

Japan’s MoF seen as another opponent to premium system

29-10-2013

The Budget Bureau of Japan’s Ministry of Finance, in a meeting of the Fiscal System Council last week,…

Asia-PacificGenericsPharmaceuticalPricing

European generic drugmakers call for maintenance of current robust WHO INN system

24-10-2013

The World Health Organization Consultation on International Non-proprietary Names (INN), open session…

BiosimilarsEuropeGenericsRegulation

Rise or demise of Japan’s generics by P Reed Maurer

Rise or demise of Japan’s generics by P Reed Maurer

16-10-2013

Generics in Japan are a work in progress. Presently they account for about 28% of pharmaceutical volume,…

Asia-PacificGenericsMarkets & MarketingPricing

226 to 250 of 1237 results

Back to top